aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference
June 13, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference
June 01, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines from its proprietary tRNA...
aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
May 17, 2022 08:00 ET
|
aTyr Pharma, Inc.
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate dose-dependent improvements in key physiologic and quality of life measures in context of a steroid taper. ...
aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
May 16, 2022 08:00 ET
|
aTyr Pharma, Inc.
Global pivotal EFZO-FIT™ study expected to begin in the third quarter of 2022 Primary endpoint will evaluate steroid sparing effect of efzofitimod compared to placebo SAN DIEGO, May 16, 2022 ...
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 13, 2022 16:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary...
aTyr Pharma to Present at Upcoming Investor Conferences in May
May 10, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA...
aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update
May 09, 2022 16:00 ET
|
aTyr Pharma, Inc.
Company to present clinical data for efzofitimod (ATYR1923) in pulmonary sarcoidosis at upcoming American Thoracic Society International Conference in May. Planned registrational study of efzofitimod...
aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results
May 02, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
UniVista Insurance, at the Forefront of Insurance Service Providers, Looks to Technology and Launches an Efficient App for Users in Florida, Texas, California and Arizona
April 25, 2022 15:01 ET
|
UniVista Insurance
MIAMI, April 25, 2022 (GLOBE NEWSWIRE) -- UniVista Insurance, in its desire to offer the best service to consumers in the shortest time possible, has launched an innovative application that brings...
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis
April 13, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, April 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...